1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Safety and clinical outcomes
All Patients (n = 44)IV Tirofiban (n = 25)IA Tirofiban (n = 19)P Value
Early symptomatic vessel re-occlusion (24 hr) (No. %)2 (4.5%)2 (8.0%)0 (0%).207
Degree of recanalization at follow-up (No. %).010
Complete recanalization/stenosis <50%22 (68.8%)13 (56.5%)9 (100%)
 Stenosis >50%6 (18.8%)6 (26.1%)0 (%)
 Occlusion4 (12.5%)4 (17.4%)0 (0%)
NIHSS at 24 hr (median, IQR)11 (5−18)9 (5−15)14 (7−21).079
NIHSS at discharge (median, IQR)8 (2−15)8 (2−14)9 (4−21).256
sICH (No. %)3 (6.8%)2 (8.0%)1 (5.3%).721
Postprocedural SAH (No. %)11 (25.0%)5 (20.0%)6 (31.6%).380
90-Day mortality (No. %)9 (18.2%)3 (12.0%)5 (26.3%).223
90-Day mRS 0−2 (No. %)18/39 (46.2%)10/23 (43.5%)8/16 (50.0%).688
90-Day mRS 0−3 (No. %)26 (59.1%)16 (64.0%)10 (52.6%).447